GSK Acquires US Biotech IDRx in $1.15 Billion Deal to Advance Rare Cancer Treatment

The acquisition secures GSK access to IDRx's precision therapies for gastrointestinal stromal tumors, addressing a significant gap in cancer care.

GSK will pay $1 billion upfront and up to $150 million in milestone payments to acquire Massachusetts-based IDRx.
IDRx specializes in therapies for gastrointestinal stromal tumors (GIST), a rare digestive system cancer affecting tens of thousands globally each year.
The deal includes IDRx's lead experimental drug, IDRX-42, which targets mutations in the KIT gene linked to tumor growth and has shown promise in early clinical trials.
GSK aims to accelerate the development of IDRX-42 in 2025, potentially redefining treatment options for GIST patients after two decades without significant advancements.
This acquisition aligns with GSK's strategy to expand its oncology portfolio and address unmet medical needs in gastrointestinal cancers.